Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

Poster presentation 2

855 - Clinicopathological features of primary malignant melanoma of the vagina


20 Dec 2015


Poster presentation 2


Hidetaka Nomura


Annals of Oncology (2015) 26 (suppl_9): 80-84. 10.1093/annonc/mdv525


H. Nomura1, A. Takahashi2, T. Usami2, M. Matoda2, H. Kanao2, E. Kondo1, K. Omatsu1, K. Kato1, Y. Takazawa3, N. Takeshima1

Author affiliations

  • 1 Gynecology, Cancer Institute Hospital of JFCR, 135-8550 - Tokyo/JP
  • 2 Gynecology, Cancer Institute Hospital of JFCR, Tokyo/JP
  • 3 Pathology, Cancer Institute Hospital of JFCR, 135-8550 - Tokyo/JP


Abstract 855


Primary malignant melanoma of the vagina (PMMV) is extremely rare, and it accounts for less than 0.15% of all female genital tract malignancies. An appropriate and effective treatment protocol for PMMV remains to be defined.The aim of this study was to identify the clinicopathologic features and treatment outcome of primary malignant melanoma of the vagina (PMMV).


This study reviewed the clinical records of ten patients who were diagnosed and treated for PMMV at Cancer Institute Hospital between September 1993 and July 2015.


Surgery was performed on eight patients; radiation therapy as an initial treatment was administered on two patients. One patient had liver and lung metastasis initially. Among the nine patients whose lesions were confined to vagina, seven patients had recurrent tumors; five of seven patients (71.4%) had distant metastasis. Among the seven patients who developed recurrence, median time for recurrence was seven months (range 1–9 months), and median overall survival was 14 months (range 4–45 months).


Distant metastasis is commonly seen within a year in a patient with PMMV whose lesions were initially thought to be confined to the vagina. In addition to the complete removal of the tumor, adjuvant systemic therapy may be the key to achieve favorable prognosis.

Clinical trial identification


All authors have declared no conflicts of interest.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings